Abstract
The NfL and S100B values for aSAH patients within 12 days of admission were considerably associated with Hunt-Hess grade, WFNS, and Fisher grade. The higher the grade, the higher the NfL and S100B value, and the poorer the prognosis. Serum NfL and S100B values could be feasible biomarkers to predict the clinical prognosis of patients with aSAH.
Introduction
Aneurysmal subarachnoid hemorrhage (aSAH)—a type of stroke caused by a ruptured intracranial aneurysm—is a critical condition with high mortality and significant long-term disability. Currently, clinical management relies on subjective grading scales like the Hunt-Hess or the World Federation of Neurological Surgeons (WFNS) scale to assess severity and predict outcomes. However, these scales often fail to capture the full extent of "early brain injury" (EBI), which involves complex cellular damage to both axons and glial cells. There is a pressing need for objective, blood-based biomarkers that can quantify this damage to guide treatment and provide families with more accurate prognoses.
Methods
Researchers conducted a prospective study of 91 aSAH patients (diagnosed at Dujiangyan Medical Center, China) and 25 healthy controls over a five-year period. The study tracked two specific protein biomarkers:
- Neurofilament light chain (NfL): A structural protein found in axons; its presence in the blood indicates axonal damage.
- S100B: A protein primarily found in glial cells; its presence indicates glial damage or blood-brain barrier disruption.
A technical highlight of the study was the use of the Simoa (Single Molecule Array) technique to measure NfL. Simoa is approximately 125 times more sensitive than traditional ELISA tests, allowing for the detection of minute protein concentrations. S100B was measured using standard ELISA. Blood samples were collected longitudinally on days 0, 1, 3, and 10–12 post-hemorrhage. Clinical outcomes were measured at 6 months using the modified Rankin Scale (mRS), where a score of 0–2 is considered a "good" outcome.
Results and Key Insights
The study demonstrated that serum NfL and S100B levels are powerful indicators of cellular trauma following aSAH.
Temporal Dynamics and Severity Correlation
Biomarker levels were not static; they increased significantly over the first 12 days post-hemorrhage. This suggests that secondary damage following the initial bleed—such as vasospasms or neuroinflammation—continues to drive up protein levels.
As illustrated in Figure 6, biomarker levels scaled almost perfectly with established clinical grades. Patients with higher Hunt-Hess or Fisher grades (indicating more severe bleeds) had significantly higher serum concentrations of both proteins ($P < 0.01$).
Predictive Accuracy
Both markers showed exceptional predictive power for 6-month mortality and functional outcomes:
- NfL: Demonstrated an Area Under the Curve (AUC) of 0.959 for predicting mortality, with a sensitivity of 94.7% and a specificity of 84.9%.
- S100B: Achieved an AUC of 0.912 for mortality prediction.
NfL appeared to be the superior predictor, suggesting that axonal injury may be the definitive driver of long-term disability in these patients. The study established specific admission "cutoff" values (14.275 pg/ml for NfL and 26.54 pg/ml for S100B) that could theoretically flag high-risk patients immediately upon admission.
Limitations and Future Work
While promising, the study has limitations. The sample size was relatively small (91 patients) and drawn from a single medical center. Additionally, the study did not directly correlate biomarker levels with axonal injury as visualized on advanced MRI (such as Diffusion Tensor Imaging). Future research should involve larger, multi-center cohorts and explore the use of a multi-protein biomarker panel to further refine diagnostic accuracy.
Conclusion
Serum NfL and S100B are objective, highly sensitive biomarkers that correlate with the clinical severity of aSAH. Integrating these ultra-sensitive protein assays into standard neuro-critical care could enable more personalized, data-driven management of patients suffering from brain hemorrhages.
Summary updated